

Haematologica
HAEMATOL/2016/144253
Version 4

Pretransplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia

Betül Oran, Jeff L. Jorgensen, David Marin, Sa Wang, Sairah Ahmed, Amin M. Alousi, Borje S. Andersson, Qaiser Bashir, Roland Bassett, Genevieve Lyons, Julianne Chen, Katy Rezvani, Uday Popat, Partow Kebriaei, Keyur Patel, Gabriela Rondon, Elisabeth J. Shpall, and Richard E. Champlin

Disclosures: Dr. Andersson has consulting/advisory role a patent/intellectual property interest in Otsuka America. Dr. Bashir had stock or other ownership interest in Kite Pharma. Dr. Bashir have research funding from Celgene and Millennium Pharmaceuticals. Dr. Patel has a consulting or advisory role in Raidance Technologies. Dr. Jorgensen has stock or other ownership interests in Luminex. Genevieve Lyons has stocks or other ownership interests in ABT, ABBV, BAX, JNJ, SYK Pharmaceuticals. Dr. Champlin has a consulting or advisory role in Sanofi and research funding from Celgene.

Contributions: B.O., R.E.C. and J.L.L. designed research, performed research, analyzed data, and wrote the paper. D.M., S.A., A.A., B.S.A, Q.B., K.R., P.K., U.P., E.J.S analyzed data and wrote the paper. S.W., R.B., G.L, J.C, G.R., performed research, analyzed data and wrote the paper.